Determination of optimal fiducial marker across image-guided radiation therapy (IGRT) modalities: Visibility and artifact analysis of gold, carbon, and polymer fiducial markers

Journal of Applied Clinical Medical Physics

Volumn 13, Issue 5, 2012, Pages 181-189

  Handsfield, Lydia L ^a   Yue, Ning J ^a   Zhou, Jinghao ^a   Chen, Ting ^a   Goyala, Sharad ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Computed tomography (CT); Fiducial marker; Image guided radiation therapy (IGRT); Kilovoltage (kV); Tomotherapy

Indexed keywords

EID: 84867058433     PISSN: None     EISSN: 15269914     Source Type: Journal    
DOI: 10.1120/jacmp.v13i5.3976     Document Type: Article

References (22)

1. Britton KR, Takai Y, Mitsuya M, Nernoto K, Ogawa Y, Yarmada S. Evaluation of inter- and intrafraction organ motion during intensity modulated radiation therapy (IMRT) for localized prostate cancer measured by a newly developed on-board image-guided system. Radiat Med. 2005;23(1):14-24.
2. Killoran JH, Kooy HM, Gladstone DJ, Welte FJ, Beard CJ. A numerical simulation of organ motion and daily setup uncertainties: implications for radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37(1):213-21.
3. Huang E, Dong L, Chandra A, et al. Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53(2):261-68.
4. Schiffner DC, Gottschalk AR, Lometti M, et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys. 2007;67(2):610-19.
5. Skarsgard D, Cadman P, El-Gayed A, et al. Planning target volume margins for prostate radiotherapy using daily electronic portal imaging and implanted fiducial markers. Radiat Oncol. 2010;5:52.
6. Khosa R, Nangia S, Chufal KS, Ghosh D, Kaul R, Sharma L. Daily online localization using implanted fiducial markers and its impact on planning target volume for carcinoma prostate. J Cancer Res Ther. 2010;6(2):172-78.
7. Gauthier I, Carrier JF, Beliveau-Nadeau D, Fortin B, Taussky D. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment. Int J Radiat Oncol Biol Phys. 2009;74(4):1128-33.
8. Welsh JS, Berta C, Borzillary S, et al. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy. Technol Cancer Res Treat. 2004;3(4):359-64.
9. Cheung J, Kudchadker RJ, Zhu XR, Lee AK, Newhauser WD. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer. Phys Med Biol. 2010;55(23):7135-47.
10. Gall KP, Verhey LJ, Wagner M. Computer-assisted positioning of radiotherapy patients using implanted radiopaque fiducials. Med Phys. 1993;20(4):1153-59.
11. Johnston ML, Vial P, Wiltshire KL, et al. Daily online bony correction is required for prostate patients without fiducial markers or soft-tissue imaging. Clin Oncol (R Coll Radiol). 2011;23(7):454-59.
12. Van Der Wielen GJ, Mutanga TF, Incrocci L, et al. Deformation of prostate and seminal vesicles relative to intraprostatic fiducial markers. Int J Radiat Oncol Biol Phys. 2008;72(5):1604-11.
13. Giebeler A, Fontenot J, Balter P, Ciangaru G, Zhu R, Newhauser W. Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer. J Appl Clin Med Phys. 2009;10(1):2875.
14. Newhauser WD, Koch NC, Fontenot JD, et al. Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy. Phys Med Biol. 2007;52(13):3979-90.
15. Verhaegen F and Palmans H. Secondary electron fluence perturbation by high-Z interfaces in clinical proton beams: a Monte Carlo study. Phys Med Biol. 1999;44(1):167-83.
16. Lim YK, Kwak J, Kim DW, et al. Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1609-16.
17. Kassim I, Joosten H, Barnhoorn JC, en BJ, Dirkx ML. Implications of artefacts reduction in the planning CT originating from implanted fiducial markers. Med Dosimetry. 2010;36(2):19-25.
18. Yazdi M, Gingras L, Beaulieu L. An adaptive approach to metal artifact reduction in helical computed tomography for radiation therapy treatment planning: experimental and clinical studies. Int J Radiat Oncol Biol Phys. 2005;62(4):1224-31.
19. Liu PT, Pavlicek WP, Peter MB, Spangehl MJ, Roberts CC, Paden RG. Metal artifact reduction image reconstruction algorithm for CT of implanted metal orthopedic devices: a work in progress. Skeletal Radiol. 2009;38(8):797-802.
20. Newhauser W, Fontenot J, Koch N, et al. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate. Phys Med Biol. 2007;52(11):2937-52.
21. Chow JC and Grigorov GN. Dose measurements near a non-radioactive gold seed using radiographic film. Phys Med Biol. 2005;50(18):N227-N234.
22. Chow JC and Grigorov GN. Monte Carlo simulations of dose near a nonradioactive gold seed. Med Phys. 2006;33(12):4614-21.